Diabetes Drug May Mimic Exercise Benefits for Prostate Cancer Patients

Metformin found to elevate Lac-Phe, a molecule linked to physical activity, offering new supportive care insights.

Apr. 10, 2026 at 2:51am

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the intricate molecular structure of a metformin pill, conceptually illustrating how this diabetes drug may be able to provide exercise-like metabolic advantages for prostate cancer patients.A closer look at the molecular mechanisms behind metformin's potential to mimic the metabolic benefits of exercise for cancer patients.Today in Miami

A study from the University of Miami's Sylvester Comprehensive Cancer Center has discovered that the diabetes medication metformin can raise levels of Lac-Phe, a molecule typically associated with intense exercise, in prostate cancer patients. This finding suggests metformin may be able to replicate some of the metabolic benefits of physical activity for those unable to exercise due to cancer treatment side effects.

Why it matters

Many cancer patients struggle to exercise due to fatigue, hormone therapy side effects, and advanced disease, creating a 'cruel paradox' where those who could benefit most from exercise are least able to do it. This study offers a potential solution by showing how a common drug can mimic the metabolic signals of physical activity, which could improve quality of life, treatment tolerance, and long-term recovery.

The details

Researchers found that metformin, a drug millions take for diabetes, can elevate levels of Lac-Phe in prostate cancer patients, even when they are not exercising. Lac-Phe is a molecule that spikes during intense physical activity and is a marker of how the body manages energy and weight under stress. Cancer treatment often disrupts metabolism, leading to weight gain, insulin resistance, and cardiovascular risks, so boosting Lac-Phe with metformin may help maintain metabolic stability.

  • The study was published in April 2026 in the journal EMBO Molecular Medicine.

The players

University of Miami's Sylvester Comprehensive Cancer Center

A National Cancer Institute-designated comprehensive cancer center that conducts research on new cancer treatments and supportive care approaches.

Got photos? Submit your photos here. ›

What they’re saying

“What if a simple pill could mimic some of the metabolic benefits of exercise for prostate cancer patients? It sounds like science fiction, but recent research suggests this might not be as far-fetched as it seems.”

— Saturnina Altenwerth, Author

What’s next

Researchers plan to further investigate metformin's effects on Lac-Phe and other metabolic markers in larger clinical trials involving prostate cancer patients.

The takeaway

This study challenges conventional cancer care approaches by showing how existing drugs can be leveraged to address metabolic challenges, even when physical exercise is not an option. The findings suggest a future of more holistic cancer support focused on helping patients thrive, not just survive.